Recombinant Transforming Growth Factor $\beta_1$ and $\beta_2$ Protect Mice from Acutely Lethal Doses of 5-Fluorouracil and Doxorubicin

By Krzysztof Grzegorzewski,* Francis W. Ruscetti,‡ Noriko Usui,‡ Giovanna Damia,§ Dan L. Longo,¶ Joseph A. Carlino,§
Jonathan R. Keller,* and Robert H. Wiltrout§

From the *Biological Carcinogenesis and Development Program, PRI/DynCorp; the ‡Laboratory of Leukocyte Biology; the §Laboratory of Experimental Immunology; and ¶Biological Response Modifiers Program, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702-1201; and §Celtrix Pharmaceuticals, Santa Clara, California 95054-1815

Summary

Transforming growth factor $\beta_1$ (TGF-$\beta_1$) and TGF-$\beta_2$ can reversibly inhibit the proliferation of hematopoietic progenitor cells in vivo, leading us to hypothesize that such quiescent progenitors might be more resistant to high doses of cell cycle active chemotherapeutic drugs, thereby allowing dose intensification of such agents. Initial studies showed that whereas administration of TGF-$\beta_1$ or TGF-$\beta_2$ did not prevent death in normal mice treated with high doses of 5-fluorouracil (5-FU), those mice that received TGF-$\beta_2$ did exhibit the beginning of a hematologic recovery by day 11 after administration of 5-FU, and were preferentially rescued by a suboptimal number of transplanted bone marrow cells. Subsequently, it was found that the administration of TGF-$\beta_2$ protected recovering progenitor cells from high concentrations of 5-FU in vitro. This protection coincided with the finding that significantly more progenitors for colony-forming unit-culture (CFU-c) and CFU-granulocyte, erythroid, megakaryocyte, macrophage (GEMM) were removed from S-phase by TGF-$\beta$ in mice undergoing hematopoietic recovery than in normal mice. Further studies showed that the administration of TGF-$\beta$ protected up to 90% of these mice undergoing hematologic recovery from a rechallenge in vivo with high dose 5-FU, while survival in mice not given TGF-$\beta$ was <40%. Pretreatment of mice with TGF-$\beta_1$ or TGF-$\beta_2$ also protected 70–80% of mice from lethal doses of the noncycle active chemotherapeutic drug, doxorubicin hydrochloride (DXR). These results demonstrate that TGF-$\beta$ can protect mice from both the lethal hematopoietic toxicity of 5-FU, as well as the nonhematopoietic toxicity of DXR. This report thus shows that a negative regulator of hematopoiesis can be successfully used systemically to mediate chemoprotection in vivo.

Myelosuppression is the dose-limiting factor for most cancer chemotherapeutic agents (1). The resulting granulocytopenia renders many patients susceptible to opportunistic infections that can be lethal (2). Agents that protect the myeloid and lymphoid systems from the suppressive effects of radiation or chemotherapy could be beneficial because the side effects induced by a standard therapy regimen might be ameliorated, and the higher doses of therapy that could be administered could result in increased antitumor efficacy (3). Two basic approaches have been envisioned to induce chemoprotection. In one approach, positive regulators of hematopoiesis, such as IL-1, IL-6, the CSFs, and/or stem cell factor could be used to stimulate the proliferation and/or production of critical stem, progenitor, or end-stage hematopoietic cells. This approach could result in a larger pool of these cells before chemotherapy, thus allowing a more rapid recovery. Alternatively, they may be used posttreatment to restimulate the remains of the stem/progenitor compartment after myelosuppression. The validity of this type of approach is illustrated by the well-documented chemoprotective effects of IL-1 (4–7). Alternatively the number of critical stem/progenitor cells could be increased and then a potent negative regulator of hematopoiesis used to temporarily inhibit their...
proliferation thereby rendering them more resistant to killing by cell cycle–active chemotherapeutic drugs. Several cytokines, including TGF-β, have been demonstrated to be potent negative regulators of hematopoiesis (8–12).

TGF-β is a 25-kD homodimeric member of a functionally related family of polypeptide growth factors that show diverse effects on growth and cell development (13–16). TGF-β exists in at least five isoforms (17), which exhibit 70–80% sequence identity (14). TGF-β1 and/or TGF-β2 have been shown to preferentially inhibit the proliferation and differentiation of early murine and human hematopoietic progenitors both in vitro and in vivo (18–25). Such cell cycle–arrested progenitors could be more resistant to cycle-active chemotherapeutic drugs, thereby allowing a dose intensification of such agents.

In this report we demonstrate that in vivo treatment with TGF-β1 or TGF-β2 protects some of the progenitors for CFU–culture (CFU-c), CFU–granulocyte, erythroid, megakaryocyte, macrophage (CFU–GEMM) and high proliferative potential–colony forming cells (HPP-CFC) in normal and hyperproliferative marrow from the toxicity of 5-fluorouracil (5-FU), thereby resulting in an ability to successfully dose intensify 5-FU. We also report that recombinant rTGF-β is effective in vivo in protecting mice from acutely toxic doses of doxorubicin hydrochloride (DXR), through effects that exist in at least five isoforms (17), which exhibit 70–80% sequence identity (14). TGF-β1 and/or TGF-β2 have been demonstrated to be potent negative regulators of hematopoiesis (8–12).

In vivo Protection of CFU-S and CFU–GEMM. In this report we demonstrate that in vivo treatment with TGF-β1 or TGF-β2 protects some of the progenitors for CFU–culture (CFU-c), CFU–granulocyte, erythroid, megakaryocyte, macrophage (CFU–GEMM) and high proliferative potential–colony forming cells (HPP-CFC) in normal and hyperproliferative marrow from the toxicity of 5-fluorouracil (5-FU), thereby resulting in an ability to successfully dose intensify 5-FU. We also report that recombinant rTGF-β is effective in vivo in protecting mice from acutely toxic doses of doxorubicin hydrochloride (DXR), through effects that exist in at least five isoforms (17), which exhibit 70–80% sequence identity (14). TGF-β1 and/or TGF-β2 have been demonstrated to be potent negative regulators of hematopoiesis (8–12).

Materials and Methods

Mice. Specific pathogen-free BALB/c mice at 8–12 wk of age were obtained from the animal production facility of the National Cancer Institute–Frederick Cancer Research and Development Center (Frederick, MD).

Growth Factors and Reagents. The rTGF-β1 was a generous gift from Dr. M. Palladino, Jr. (Genentech Inc., San Francisco, CA). The rTGF-β1 was produced in Chinese hamster ovary cells and generously supplied by Celtrix Pharmaceuticals (Santa Clara, CA). For injection, the TGF-β1 was diluted in HBSS + 0.1% normal mouse serum (NMS) and TGF-β2 in citrate buffer (pH 6.0) containing 1% NMS. TGF-β1 or TGF-β2 were administered intraperitoneally according to various protocols outlined in the figure legends. Recombinant murine IL-3 and recombinant human erythropoietin (rEpo) were purchased from ProProTech, Inc. (Rocky Hill, NJ), and Amgen Biologics (Thousand Oaks, CA), respectively. 5-FU (LymphMed, Rosemont, IL) was diluted in sterile distilled water and administered intravenously to the mice at the indicated doses while DXR (Sigma Chemical Co., St. Louis, MO) was diluted in HBSS immediately before intraperitoneal injection.

CFU-c and CFU–GEMM Assay. BM cells were aspirated from the paired femurs and tibiae of control or experimental mice with cold HBSS without Ca2+ and Mg2+ (washing buffer), washed twice, and resuspended in α medium (GIBCO BRL, Gaithersburg, MD) that was supplemented with 20% FCS (Biofluids, Inc., Rockville, MD), 2 × 10−4 mol/liter hemin (Sigma Chemical Co.), 5 × 10−4 mol/liter 2-mercaptoethanol (Sigma Chemical Co.), 8 U/ml Epo, 100 U/ml rhIL-3, and 0.05 mg/ml gentamicin in 0.35% Sea-plaque agarose. FMC Bioproducts, Rockland, ME). 105 BM cells in 1 ml of this medium were plated in 35-mm Lux petri dishes (Miles Laboratories, Inc., Naperville, IL) and incubated at 37°C in 5% CO2 for 10 d at which time the number of colonies was determined. Multipotential colonies containing granulocyte, erythroid, megakaryocyte and macrophage lineages were scored as CFU–GEMM, while monocyte (CFU-M), myeloid (CFU-G), erythroid (CFU-c, BFU-e), and myelomonocytic (CFU-GM) colonies were designed as CFU-c (26). Data are presented as the total number of CFU obtained from the paired femurs and tibiae of each mouse.

HPP-CFC Assay. HPP-CFC were detected using a modified double-layer agar technique (27). Briefly, lower layers (0.5% agarose in α medium/20% FCS containing hemin, IL-3, IL-1, and supernatant from L929 cells [source of CSF-1]) were prepared in 35-mm Lux petri dishes, and 2–8 × 104 cells in 0.35% agarose in α medium/20% FCS was added as a second layer. Cultures were scored after incubation for 14 d under low oxygen tension (7.5% O2/7.5% CO2/85% N2). All colonies with a diameter >0.5 mm were scored as HPP-CFC.

Thymidine Suicide Assay. The proliferative status of various hematopoietic progenitors was measured by calculating the percentage of CFU-c and CFU–GEMM remaining after incubation with methyl[3H]thymidine (37.0 MBq/ml, sp act 925 GBq/mmol) (Amersham Corp., Arlington Heights, IL) as previously described (28, 29). BM cells were resuspended in culture medium (α medium/20% FCS) at a concentration of 2 × 105 cells/ml and incubated with 100 μCi/ml of [3H]thymidine for 30 min at 37°C. The incubation was terminated by placing the cell suspensions on ice. CFU-c and CFU–GEMM assays were initiated immediately after washing the cells twice with cold thymidine at 100 μg/ml and plating was done in cold thymidine at 10 μg/ml.

Statistical Analysis. All statistical evaluations were performed using computer software; Instat version 2.02 or GraphPad Prism version 1.0 (GraphPad Software, San Diego, CA). The significance of the differences between groups was evaluated by analysis of variance followed by two-tailed Student’s t test. A two-way analysis of variance test was used to determine statistical significance of treatment on cell cycle. Results from survival experiments were analyzed using a log-rank nonparametric test and expressed as Kaplan–Meier survival curves.

Results

Pretreatment with rTGF-β1 In Vivo Delays Progenitor Recovery In Mice Subsequently Treated with a Sublethal Dose of 5-FU. The results presented in Fig. 1 demonstrate that although pretreatment with rTGF-β1 initially decreased the formation of all progenitors by day 9 after injection with a sublethal dose of 5-FU, the later recovery that occurs by the end of the rebound phase (days 13–15) exceeded the rebound levels observed for mice that received only 5-FU. This effect was significant at the p < 0.001 level for both CFU-c and HPP-CFC, with CFU–GEMM numbers also showing a trend toward an increase.

Pretreatment of Normal Mice with TGF-β1 and TGF-β2 Does

1048 rTGF-β1 and β-2 Protect Mice from In Vivo 5-Fluorouracil and Doxorubicin
Not Protect Mice against Lethal Doses of 5-FU. Because of the enhanced late hematopoietic recovery noted in the results presented in Fig. 1, we speculated that TGF-β pretreatment might protect enough CFU progenitors from the toxic effects of higher doses of 5-FU that these mice might survive an otherwise lethal injection of 5-FU. However, mice that were pretreated twice daily with TGF-β (2.5 μg/dose) for 5 d consecutively were actually less resistant to high doses of 5-FU (200 mg/kg 5-FU [LD₅₀] vs. TGF-β₁ + 200 mg/kg 5-FU [LD₅₀], p < 0.01, and 250 mg/kg 5-FU [LD₅₀] vs. TGF-β₁ + 250 mg/kg 5-FU [LD₅₀], p < 0.01; Fig. 2 A). Pretreatment with TGF-β₂ also was found to potentiate the toxicity of high (340 mg/kg) dose [LD₇₀] 5-FU such that no mice survived (Fig. 2 B). Lower daily doses of TGF-β₂ did not potentiate 5-FU-induced toxicity, but neither was protection induced. A series of additional studies using pretreatment with either TGF-β₁ or TGF-β₂ demonstrated only increased toxicity, not protection (data not shown).

Reversal of TGF-β₂-potentiated 5-FU-induced Toxicity by BM Transplant (BMT). Myelotoxicity as the cause of death in mice treated with TGF-β₁ and 5-FU was confirmed by pretreating mice with TGF-β₁ for 5 d consecutively before a bolus injection of high dose (250 mg/kg) 5-FU [LD₅₀] on day 0 and subsequent syngeneic BMT (10⁷ cells) on days 2,
number of BM day 14. The data are presented as the mean Figure from High Doses of 5-FU.

intraperitoneally with (2.5 &g/dose) rTGF-ß1 and a

geneic BMT (10^7 of rTGF-ß1). On days 2, 3, and 4 followed by a bolus injection of 5-FU (250 mg/kg) 2 h

survival. 3, and 4 (Fig. 3). As expected from the data shown previously in Fig. 2, none of the mice treated with both TGF-ß1 and 5-FU survived (5-FU alone [LD50] vs. TGF-ß1 + 5-FU [LD100], p <0.01). However, 80% of the mice treated with TGF-ß1 and 5-FU followed by BMT survived (TGF-ß1 + 5-FU [LD100] vs. TGF-ß1 + 5-FU + BMT [LD30], p <0.01), confirming that the increased toxicity of 5-FU by TGF-ß1 was predominantly hematologic.

TGF-ß Protects Some Progenitors and Mature Myeloid Cells from High Doses of 5-FU. As previously noted, mice that were pretreated with TGF-ß2 for 5 d consecutively exhibited an enhanced toxicity (LD100 0.25 &g/dose and LD50 at 0.1 &g/dose of TGF-ß2) after high dose (340 mg/kg) 5-FU [LD50]. However, analysis of progenitor levels (Fig. 4, A and B) revealed a significant (p <0.001) increase in the number of CFU-GEMM and CFU-c in mice pre-treated daily with 0.25 &g of TGF-ß2 as compared with mice treated only with 5-FU (CFU-GEMM at day 7: 4-fold increase, p <0.001, and at day 11: 7.5-fold increase, p <0.001; and CFU-c at day 7: 3-fold increase, p <0.001, and at day 11: 12-fold increase, p <0.001). Furthermore, the lower daily dose of TGF-ß2 (0.1 &g), while less efficient than a higher dose (0.25 &g) in facilitating the recovery of CFU-c at an earlier time point (day 7: 280 ± 8 vs. 620 ± 13), was equally effective to the higher dose in enhancing CFU-c at a later time point (day 11: 5010 ± 322 vs. 5365 ± 209). The 0.1 &g daily dose also was efficient in protecting CFU-GEMM on day 11 as compared with mice treated only with 5-FU (185 ± 19 vs. 40 ± 3, p <0.001). This recovery of CFU by day 11 in TGF-ß2-pretreated mice was substantial in that the number of CFU-c was ~30% of normal for either dose of TGF-ß2, whereas the number of CFU-GEMM was 29 and 18% of normal for TGF-ß2 doses of 0.25 and 0.1 &g, respectively. These levels of CFU-c and CFU-GEMM were 12-fold and 7.5-fold, respectively, higher in the TGF-ß-pretreated mice than in those that only received 5-FU. Similarly, an analysis of total BM cellularity (Fig. 4, C) showed that mice pretreated with TGF-ß2 exhibited some rebound by day 11 (1.5 x 10^6 and 1.6 x 10^6 cells) when given daily TGF-ß2 doses of 0.25 and 0.1 &g, respectively, as compared with 0.4 x 10^6 cells in mice treated only with 5-FU.

Mice That Are Pretreated with TGF-ß2 before High Dose 5-FU Are More Easily Reconstituted with BM Cells Than Mice Only Given 5-FU. The results presented in Fig. 4 demonstrate that pretreatment with TGF-ß did protect some progenitors, suggesting such protection did not translate to ex-

![Figure 3. Effect of BM transfer on survival of mice treated with rTGF-ß and a high sublethal dose of 5-FU. Mice (n = 10) were injected intraperitoneally with (2.5 &g/dose) or rTGF-ß for 5 d consecutively followed by a bolus injection of 5-FU (250 mg/kg) 2 h after the last injection of rTGF-ß1. On days 2, 3, and 4 some mice were given intravenous syngeneic BMT (10^7 cells). All mice were then monitored for toxicity and survival.](image)

![Figure 4. Effect of pretreatment with rTGF-ß on progenitors in mice subsequently treated with a lethal dose (340 mg/kg) of 5-FU. Mice (n = 10) were injected intraperitoneally with 0.25 or 0.1 &g of rTGF-ß twice daily on days −4–0. On day 0, 2 h after the last injection of rTGF-ß2, all mice were injected intravenously with 5-FU. Groups of mice were killed and BM was obtained at various times after the injection of 5-FU. The total number of BM cells obtained from the paired femurs and tibias of each mouse was determined before the colony assay was performed and read on day 14. The data are presented as the mean ± SD for three replicates of a pooled cell population and the total CFU/mouse was calculated based on their frequency multiplied by the total cellularity per mouse.](image)
tended survival, because the number of progenitors protected fell below a critical threshold. To test this hypothesis, mice were treated with TGF-β2 (0.1 μg/dose) or vehicle control (citrate buffer) for 5 d consecutively followed by a bolus injection of an acutely lethal [LD₅₀] dose of 5-FU (340 mg/kg). Some mice then received a suboptimal BMT (10⁶) on days 1, 3, 6, and 9 (Fig. 5). Reconstitution of mice treated only with 5-FU [LD₅₀] by suboptimal BMT did not significantly increase in survival [LD₅₀] (p >0.1), whereas the group that had been pretreated with TGF-β₂ before 5-FU [LD₅₀] exhibited a significantly improved (p <0.001) survival of 90% [LD₅₀] after suboptimal BMT.

In Vivo Administration of TGF-β₁ or TGF-β₂ Protects Regenerating Progenitor Cells from 5-FU In Vitro. The results presented in Figs. 1, 4, and 5 demonstrate that TGF-β spares some critical short-term repopulating progenitors in mice from the acutely toxic effects of 5-FU, suggesting that these cells are more resistant to direct killing by 5-FU. This hypothesis was confirmed by treating mice with rTGF-β₁ (2.5 μg/mouse twice daily) (experiment 1) or rTGF-β₂ (0.1 μg/mouse once a day) (experiment 2) on days 7-11 of the subsequent hyperproliferative recovery phase that follows a sublethal dose (150 mg/kg) of 5-FU. Progenitors for CFU-c (Fig. 6 A) and CFU-GEMM (Fig. 6 B) obtained from mice that had received rTGF-β₁ or TGF-β₂ in addition to 5-FU were more resistant to the direct toxic effects of 5-FU in vitro. Specifically the percent decrease in total CFU-c number after exposure to 10 μg/ml or 25 μg/ml 5-FU in vitro was 70 and 93%,
Table 1. Effect of rTGF-β2 Administration In Vivo on Subsequent Sensitivity of HPP-CFC Progenitor Cells to 5-FU In Vitro

| In vivo treatment | In vitro treatment | Number of HPP-CFC recovered | Percent decrease from control mice (media only) | Fold increase in HPP-CFC formation* |
|------------------|------------------|-----------------------------|-----------------------------------------------|-----------------------------------|
| 5-FU             | Media only       | 576 ± 77                    | N/A†                                          | N/A                               |
| 5-FU (10 μg/ml)  | 5-FU (10 μg/ml)  | 132 ± 46                    | 77                                            | N/A                               |
| 5-FU (25 μg/ml)  | 5-FU (25 μg/ml)  | 115 ± 40                    | 80                                            | N/A                               |
| 5-FU rTGF-β2     | Media only       | 682 ± 48                    | N/A†                                          | 0.2                               |
| 5-FU (10 μg/ml)  | 5-FU (10 μg/ml)  | 544 ± 91                    | 20                                            | 3.1                               |
| 5-FU (25 μg/ml)  | 5-FU (25 μg/ml)  | 398 ± 99                    | 42                                            | 2.5                               |

Mice (*n = 5*) were injected intravenously on day 0 with 150 mg/kg of 5-FU. Mice received 0.1 μg of rTGF-β2, BID on days 7-11, and once on the morning of day 12. 2 h after the last injection of rTGF-β2, all mice were killed and the BM cells were harvested. BM samples from each group were then treated for 2 h in vitro with media only, 10 μg/ml of 5-FU, and 25 μg/ml of 5-FU. The cells were then washed, recounted, and plated in triplicate for HPP-CFC formation. The data are presented as the mean ± SD for three replicates of a pooled cell population and the total CFU/mouse was calculated based on obtained frequency multiplied by the total cellularity per paired femurs and tibias obtained after in vitro treatment. This is a representative experiment of two performed.

* Value indicates fold increase in HPP-CFC formation in mice treated in vivo with 5-FU (150 mg/kg) and rTGF-β2 compared with 5-FU alone.
† N/A, not applicable.

In addition, mice that received 5-FU plus TGF-β1 or TGF-β2 exhibited a considerably greater number of all types of CFU at the time of marrow harvest on day 12 than did mice that received only 5-FU. This effect, combined with the enhanced resistance to 5-FU in vitro, resulted in a 3.7-fold (TGF-β1) and 1.5-fold (TGF-β2) increase in the number of CFU-c and a 2.7-fold (TGF-β1) and 3.1-fold (TGF-β2) increase in the number of CFU-GEMM that remained after

Table 2. Effects of rTGF-β2 on Cycling of Progenitor Cells in Mice Previously Treated with a Sublethal Dose of 5-FU

| Progenitor type | Experimental treatment | Total no. of progenitor cells in S-phase | Percent reduction in S-phase cells by TGFβ2 |
|-----------------|-----------------------|------------------------------------------|------------------------------------------|
| CFU-c           | 5-FU                  | 19,787                                    | -                                        |
|                 | 5-FU + TGFβ2          | 400                                       | >99                                      |
|                 | Diluent               | 11,836                                    | -                                        |
|                 | Diluent + TGFβ2       | 8,433                                     | 29                                      |
| CFU-GEMM        | 5-FU                  | 4,667                                     | -                                        |
|                 | 5-FU + TGFβ2          | 1,467                                     | 69                                      |
|                 | Diluent               | 1,563                                     | -                                        |
|                 | Diluent + TGFβ2       | 613                                       | 61                                      |

Donor mice (*n = 3*) were injected intravenously with 5-FU (150 mg/kg). From day 9 to 13 mice were treated intraperitoneally with rTGF-β2 (0.1 μg/dose) or citrate buffer (diluent). 2 h after the last injection of rTGF-β2, all mice were killed and BM cells were harvested. For cell cycling analysis of various progenitors, BM cells (2 × 10⁶/ml) were cultured in the presence of [3H]TDR (100 μCi/ml) or (cold) TdR (control) for 30 min at 37°C. After treatment, BM cells (10⁶) were plated for colony forming assays. The total number of progenitor cells in S-phase was calculated by subtracting the mean number of colonies obtained after in vitro treatment with [3H]TDR from those treated with (cold) TdR, and multiplied by the total cellularity of paired donors' femurs and tibias.

1052 rTGF-β1 and β-2 Protect Mice from In Vivo 5-Fluorouracil and Doxorubicin
exposure to 10 µg/ml of 5-FU in vitro for mice treated with 5-FU plus TGF-β vs. 5-FU alone, with similar effects noted at an in vitro concentration of 25 µg/ml 5-FU for TGF-β1 or TGF-β2. This protection by TGF-β also extends to the more primitive HPP-CFC progenitors since the number surviving after exposure to 10 µg/ml or 25 µg/ml 5-FU in vitro was increased 4.1-fold and 3.5-fold, respectively, in mice that had received TGF-β2 in vivo as compared with those that did not receive TGF-β1 (Table 1). These results demonstrate that TGF-β renders various progenitor cells more resistant to direct killing by 5-FU.

Treatment of Mice with TGF-β2 during the Post-5FU Hyperproliferative Phase Decreases Cycling of CFU Progenitors. The experiment shown in Table 2 demonstrates that TGF-β2 treatment during the hyperproliferative phase of hematologic recovery after 150 mg/kg 5-FU reduces the total number of CFU-c progenitors in S-phase by 19,387 (>99%) and thereby protects them from killing by high sp act radioactive thymidine. In contrast, in normal mice, which have fewer total CFU-c progenitors in S-phase, the administration of TGF-β2 reduces the total number of CFU-c in S-phase by 3,403, or only 29%. The results for CFU-GEMM progenitors were

Figure 7. Effect of rTGF-β2 administered during the late hyperproliferative phase of mice rendered leukopenic by 5-FU on subsequent sensitivity of progenitor cells to 5-FU in vivo. Mice (n = 10) were injected intravenously on day 0 with 150 mg/kg of 5-FU. On days 9-13, mice were treated twice a day with rTGF-β2 (0.1 µg/dose) or with diluent only. On day 13, 2 h after last injection, a second high dose of 5-FU (A, 300 mg/kg; or B, 360 mg/kg) were administered. All mice were then monitored for toxicity and survival.
similar with TGF-β2 reducing the total number by 3,200 in mice recovering from 5-FU, but only by 950 in normal mice (p < 0.01).

**Treatment of Mice with TGF-β2 during the 5-FU-induced Bone Marrow Hyperproliferative Phase Protects Against High Doses of 5-FU.** Because TGF-β protects recovering marrow progenitor cells from both 5-FU and [H]thymidine, studies were performed to determine whether mice could be protected against a subsequent higher dose of 5-FU in vivo. Therefore, TGF-β1 was administered on days 9–13 (late recovery phase) after initial exposure to 150 mg/kg 5-FU, and these mice were then rechallenged with high doses (300 or 360 mg/kg) of 5-FU (Fig. 7). Mice pretreated with low dose 5-FU plus TGF-β2, followed by high doses of 5-FU (300 mg/kg [LD₉₀]) (Fig. 7 A) and 360 mg/kg [LD₉₀] (Fig. 7 B) exhibited an increased survival rate of 90%, p < 0.05 and 60%, p < 0.05, respectively, as compared with the mice that did not receive the TGF-β2 treatment (Fig. 7, A and B). This protective effect was lost if the TGF-β2 was administered on days 5–8 (early recovery phase) after 150 mg/kg 5-FU (data not shown).

TGF-β1 and TGF-β2 Protect Mice against Lethal Doses of DXR. The effects of rTGF-β on lethality induced by high doses of the anthracycline chemotherapeutic drug DXR also were studied. Surprisingly, as the data from a representative experiment show, pretreatment with TGF-β1 (Fig. 8 A) or TGF-β2 (Fig. 8 B) for 4 d protected mice in a dose-dependent manner from an acutely lethal dose (16 mg/kg) of DXR (TGF-β₁: 2.5 μg/day, 80% survival, p < 0.01; TGF-β₁: 0.5 μg twice daily, 20% survival, p < 0.01; and TGF-β₂: 0.5 μg twice daily, 70% survival, p < 0.01). Because DXR is only moderately myelosuppressive in mice, we also investigated whether the mechanism of TGF-β-mediated protection was exclusively hematopoietic (Fig. 8 C). It is interesting to note that the mortality of mice treated with a lethal dose of DXR was not reversed by a subsequent BM transfer (10⁷ cells injected 24 h after DXR administration), suggesting that the mechanism of TGF-β protection is at least partially nonhematopoietic.

**Discussion**

Myelosuppression is a major dose-limiting toxicity of many widely used cancer chemotherapeutic drugs (1, 2). Both positive and negative regulators of hematopoiesis have been proposed as potential chemoprotective agents (12). Positive regulators of hematopoiesis (e.g., CSFs, IL-1, Epo, and stem cell factor) are known to be useful in this regard (9, 12), while the application of negative regulators (e.g., TGF-β) of hematopoiesis as potential protective agents is not yet clear (30). Negative regulators might temporarily protect vital hematopoietic stem/progenitor cells in the BM by inhibiting their ability to cycle during and shortly after the delivery of chemotherapy thereby allowing either acute or chronic dose intensification (31). This hypothesis is supported by reports that TGF-β can reversibly inhibit the proliferation of CFU-S (25) and primitive hematopoietic progenitors in vitro (32), and arrest a variety of cells in middle to late G₁ phase of the cell cycle.

**Figure 8.** Chemoprotective effects of rTGF-β₁ and TGF-β₂ for DXR. Groups of mice (n = 10) were injected intraperitoneally twice a day for days: -4-0 with various doses of rTGF-β₁ (A, 0.5–2.5 μg/dose) or rTGF-β₂ (B, 0.1-0.5 μg/dose). Control groups were injected with diluents. 1-2 h after the last TGF-β injection mice were challenged with a single intraperitoneal injection (14 mg/kg) of DXR. Additionally mice injected with DXR only were also given a single injection of BM cells (10⁷) (C). All mice were then monitored for toxicity and survival.
cycle (33–35). The investigation of TGF-β as a protective agent stems from observations that TGF-β1 in the BM microenvironment may play a role in the regulation of hematopoiesis (36), TGF-β1 and TGF-β2 potently inhibit the proliferation of murine progenitor cells (11, 19), and that TGF-βs synergize in vitro with GM-CSF to increase murine granulopoiesis (36) and the number of CFU-GM (37, 38). Overall, these findings suggest that TGF-βs alter both proliferation and differentiation of hematopoietic progenitor cells.

The present studies were initiated to determine whether transient inhibition of CFU progenitor proliferation by TGF-β could be exploited to protect bone marrow stem/progenitor cells from destruction by chemotherapeutic drugs, thereby allowing dose intensification of chemotherapy. Initial experiments confirmed that pretreatment with TGF-β1 potentiated the rebound that follows administration of 150 mg/kg 5-FU, a regimen widely used to increase the number of cycling progenitor cells (39–42). However, there was also an initial delay in hematopoietic recovery of TGF-β–pretreated mice suggesting a lower proliferative response of any protected stem/progenitor cells to the positive regulatory signals that are produced physiologically in response to myelosuppression. This effect could be due to an inhibition by TGF-β of stem/progenitor cell entry into cell cycle. This point may be important since stem and progenitor cells are heterogeneous, with some in G0, some slowly entering the cycle (long lag of G1 phase), and some in cycle (43). Despite the early inhibitory effect of TGF-β on hematopoietic progenitors, the later enhanced effect suggests that the apparent inhibition of proliferation also resulted in protection of some progenitors from 5-FU–mediated toxicity.

In spite of the ability of TGF-β to allow an enhanced rebound after 5-FU, pretreatment with either TGF-β1 or TGF-β2 failed to protect normal mice against high sublethal or lethal doses of 5-FU, and actually rendered them more susceptible to lethality by 5-FU. This increased toxicity was hematological since subsequent BM transfer largely reversed the effect, suggesting that temporary inhibition of the function of a critical short-term repopulating subset of progenitor cells might prevent a timely recovery in 5-FU–treated mice, allowing the development of septicemia and death from infection. This hypothesis was supported by data showing that there was a significant increase in the number of total BM cells, CFU-c, and CFU-GEMM in mice treated with TGF-β plus high dose 5-FU vs. those treated with high dose 5-FU alone, although all mice in both groups died by around day 15. Hematologic protection by TGF-β was confirmed when mice pretreated with TGF-β before high dose 5-FU (340 mg/kg) were salvaged by a suboptimal number of bone marrow cells, suggesting that TGF-β did protect some progenitors from 5-FU–induced toxicity in normal mice, but their number and/or function was inadequate to completely protect mice during the critical time period when septicemia develops.

It is important to note that TGF-β does not potentiate the cell cycle–dependent toxic effects of 5-FU since progenitor cells obtained from mice given a sublethal dose of 5-FU followed by TGF-β were more abundant and more resistant to in vitro treatment with increasing doses of 5-FU. Thus, TGF-β altered the number of BM progenitors, and also their physiological status, suggesting that the effectiveness of TGF-β as a chemoprotective agent might be at least partially dependent on the cycling status of progenitors. This was confirmed by studies showing that TGF-β treatment dramatically reduced the number of CFU progenitors in S-phase and prevented their killing by high sp act [3H]thymidine, an effect that has been reported by Cashman et al. (32) in vitro for human progenitors in long-term culture-adherent assays, and by Migdalska et al. (25) for in vivo treatment of recovering marrow in mice. This effect was significantly more pronounced in mice recovering from 5-FU than in normal mice, and was greater for CFU-c than CFU-GEMM progenitors, supporting the hypothesis that the protection of the mature progenitors is especially critical for protection during the critical 7–10-d period after subsequent exposure to high dose 5-FU. These results speak most directly to protection of short-term marrow repopulating activity (STMRA). However, the survival curves do extend to 200 d (Fig. 7 B) suggesting that such protection also extends to the long-term marrow repopulating cells (LTMRC) reportedly spared by 5-FU (44).

Thus, protection of existing progenitors in normal mice by TGF-β is not sufficient and there is a requirement for an increased number of progenitors for successful chemoprotection. For optimal protection against cycle-dependent chemotherapeutic agents, stem/progenitor cells needed to be positively stimulated (e.g., with a low sublethal dose of 5-FU) to cause an increase in proliferation before exposure to TGF-β. Therefore, more progenitors are cycle–arrested by TGF-β, and more can quickly reenter cycle after administration of cell cycle–dependent chemotherapeutic agents.

DXR is a DNA intercalating agent that blocks topoisomerase II and is myelosuppressive in humans (1, 45). In confirmation of our earlier preliminary findings (46), we have shown that, unlike for 5-FU, the repeated preadministration of TGF-β1 or TGF-β2 to unstimulated mice protects some mice from lethal doses of DXR. Although myelosuppression is one of the dose-limiting toxicities associated with the clinical use of DXR, cardio- and intestinal toxicity are also evident (47, 48), whereas liver tissue is relatively resistant (47). In mice, the cardioprotective drug ICRF-187 (ADR-529) is able to decrease DXR-related toxicity in mice (49). TGF-β1 also has been found to ameliorate TNF-induced cardiotoxicity when given before or immediately after ischemic injury (50), to inhibit the proliferation of intestinal epithelial cells suggesting that it might protect against cell cycle–dependent gut toxicity of DXR (25, 48). In our studies, the acutely toxic effects of DXR in mice were not reversed by BMT suggesting that TGF-β–mediated protection against DXR is at least partially nonhematologic. Thus, the cell cycle–dependent protective effects of TGF-βs are not limited to the hematopoietic system since TGF-β3 has been shown to decrease proliferation of epithelial cells thereby decreasing 5-FU–induced mucositis (51).

In summary, we have demonstrated that TGF-β can protect mice against lethal doses of 5-FU and DXR. TGF-β1 has been reported to also protect against in vitro toxicity by
4-hydroxycyclophosphamide (52), and TGF-β may have some protective effects against cyclophosphamide in vivo (46).

Overall, these results suggest a possible wide spectrum of action by TGF-β as a chemoprotective agent, possibly through several different mechanisms. Our results suggest that treatment with TGF-β before chemotherapy protects some stem/progenitor cells and increases the number that might then be available for restimulation by positive hematopoietic regulators after chemotherapy. Alternatively, pretreatment with positive regulators such as the CSFs, IL-1, IL-3, or SCF followed by TGF-β might also be useful for increasing the number of regenerating progenitor cells and then protecting them from subsequent chemotherapeutic insult. Ultimately, the combined use of positive and negative regulators of hematopoiesis might allow the delivery of more dose-intensive chemotherapy with decreased time to recovery, and lead to increased antitumor effects in patients with tumors that are partially responsive to chemotherapy.

The authors thank Dr. John R. Ortaldo for his critical review of the manuscript and for helpful suggestions during the course of these studies. The authors also thank Tim Back, Patricia Echeagaray, Richard Gregory, Eliene Gruys, and Steve Stull for their excellent technical expertise; Joyce Vincent for editing; and Susan Charbonneau for preparation of this manuscript.

Address correspondence to Dr. Robert H. Wiltrout, NCI-FCRDC, Bldg. 560, Rm. 31-93, Frederick, MD 21702-1201.

Received for publication 6 January 1994 and in revised form 24 May 1994.

References

1. Chabner, B.A., and C.E. Myers. 1993. Antitumor antibiotics. In Cancer, Principles and Practice of Oncology. V.T. DeVita, Jr., S. Hellman, and S.A. Rosenberg, editors. Lippincott, Philadelphia. 374–384.

2. Pizzo, P.A. 1984. Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges. Cancer 54:2649.

3. Griswold, D.P., Jr., M.W. Trader, E. Frei, III, W.P. Peters, M.K. Wolpert, and W.R. Lastar, Jr. 1987. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy. Cancer Res. 47:2323.

4. Damia, G., K.L. Komschlies, H. Futami, T. Back, M.E. Gruys, D.L. Longo, J.R. Keller, F.W. Ruscetti, and R.H. Wiltrout. 1992. Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin-1: protection from hematological and nonhematological toxicities. Cancer Res. 52:4082.

5. Moore, M.A., R.L. Stolfi, and D.S. Martin. 1990. Hematologic effects of interleukin-1 beta, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor in tumor bearing mice treated with fluorouracil. J. Nail Cancer Inst. 82:1031.

6. Castelli, M.P., P.L. Black, M. Schneider, R. Pennington, F. Abe, and J.E. Talmadge. 1988. Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models. J. Immunol. 140:3830.

7. Futami, H., R. Jansen, M.J. MacPhee, J. Keller, K. McCormick, D.L. Longo, J.J. Oppenheim, F.W. Ruscetti, and R.H. Wiltrout. 1990. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy. J. Immunol. 145:4121.

8. Graham, G.J., and I.B. Pragnell. 1991. Negative regulators of hematopoiesis—current advances. Prog Growth Factor Res. 2:181.

9. Broxmeyer, H.E. 1992. Suppressor cytokines and regulation of myelopoiesis: biological and possible clinical uses. Am. J. Ped. Hematol/Oncol. 14:22.

10. Ruscetti, F.W., C. Dubois, S.E. Jacobsen, and J.R. Keller. 1991. Transforming growth factor β and interleukin 1: a paradigm for opposing regulation of hematopoiesis. In Growth Factors in Hematopoiesis, Bailliere's Clinical Haematology. B. Lord and T.M. Dexter, editors. W.B. Saunders, London. 703–721.

11. Keller, J.R., G.K. Sing, L.R. Ellingsworth, S.K. Ruscetti, and F.W. Ruscetti. 1990. Two forms of transforming growth factor-β are equally potent selective growth inhibitors of early murine hematopoiesis. Ann. N.Y. Acad. Sci. 593:172.

12. Moore, M.A.S. 1991. Clinical implications of positive and negative hematopoietic stem cell regulators. Blood. 78:1.

13. Massague, J. 1987. The TGF-β family of growth and differentiation factors. Cell. 49:437.

14. Roberts, A.B., and M.B. Sporn. 1990. The transforming growth factors-betas: past, present, and future. Ann. N.Y. Acad. Sci. 593:1.

15. Lyons, R.M., and H.L. Moses. 1990. Review: transforming growth factors and the regulation of cell proliferation. Eur. J. Biochem. 187:467.

16. Kulkarni, A.B., C.G. Huh, D. Becker, A. Geiser, M. Lyght, K.C. Flanders, A.B. Roberts, M.B. Sporn, J.M. Ward, and S. Karlsson. 1993. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA. 90:770.

17. Roberts, A.B., S.J. Kim, P. Kondaiah, S.B. Jakowlew, F. Denbeiz, A.B. Glick, A.G. Geiser, S. Watanabe, T. Noma, R. Lechleider, and M.B. Sporn. 1990. Transcriptional control of expression of the TGF-β. Ann. N.Y. Acad. Sci. 593:43.

18. Keller, J.R., C. Mantel, G.K. Sing, L.R. Ellingsworth, S.K. Ruscetti, and F.W. Ruscetti. 1988. Transforming growth factor β1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines. J. Exp. Med. 168:737.
1988. Transforming growth factor β selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood. 72:1504.

20. Keller, J.R., G.K. Sing, L.R. Ellingsworth, and F.W. Ruscetti. 1989. Transforming growth factor β: possible roles in the regulation of normal and leukemic hematopoietic cell growth. J. Cell. Biochem. 39:175.

21. Keller, J.R., I.K. McNiece, K.T. Sill, L.R. Ellingsworth, P.J. Quesenberry, G.K. Sing, and F.W. Ruscetti. 1990. Transforming growth factor β directly regulates primitive murine hematopoietic cell proliferation. Blood. 75:596.

22. Goey, H., J.R. Keller, T. Back, D.L. Longo, F.W. Ruscetti, and R.H. Wiltrout. 1989. Inhibition of early murine hematopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-β1. J. Immunol. 143:877.

23. Hampson, J., I.L. Ponting, N. Cook, L. Vodinelich, S. Redmond, A.B. Roberts, and T.M. Dexter. 1989. The effects of TGF β on haemopoietic cells. Growth Factors. 1:193.

24. Jansen, R., G. Damia, N. Usui, J. Keller, H. Futami, H. Goey, T.T. Back, D.L. Longo, F.W. Ruscetti, and R.H. Wiltrout. 1991. Effects of recombinant transforming growth factor-β1 on hematologic recovery after treatment of mice with 5-fluorouracil. J. Immunol. 147:3342.

25. Migdalska, A., G. Molineux, H. Demuynck, G.S. Evans, F. Ruscetti, and T.M. Dexter. 1991. Growth inhibitory effects of transforming growth factor-β1 in vivo. Growth Factors. 4:239.

26. Metcalf, D. 1984. The hematopoietic stem and progenitor cells demonstrable using in vitro cloning techniques. In The Hemopoietic Colony Stimulating Factors. D. Metcalf, editor. Elsevier, Amsterdam. 27–54.

27. Bradley, T.R., and G.S. Hodgson. 1979. Detection of primitive macrophage progenitor cells in mouse bone marrow. Blood. 54:1446.

28. Lord, B.I. 1993. In vivo assays for multipotential and marrow repopulating cells. In Haematopoeisis: A Practical Approach. N.G. Testa and G. Molineux, editors. Oxford University Press. Oxford, UK. 1–19.

29. Iscove, N.N., J.E. Till, and E.A. McCulloch. 1970. The proliferative states of mouse granulopoietic progenitor cells. Proc. Soc. Exp. Biol. Med. 134:33.

30. Bonewald, L.F. 1992. Can transforming growth factor beta be useful as a protective agent for pluripotent hematopoietic progenitor cells? Exp. Hematol. 20:1249.

31. Lord, B.I., and E.G. Wright. 1982. Potential therapeutic value of endogenous stem cell proliferation regulators. In Maturation Factors and Cancer, Progress in Cancer Research and Therapy, Vol. 23. M.A.S. Moore and D. Phil, editors. Raven Press, New York. 323–333.

32. Cashman, J.D., A.C. Eaves, E.W. Raines, R. Ross, and C.J. Eaves. 1990. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of variety of mesenchymal cell activators and inhibitory role of TGF-β. Blood. 75:96.

33. Smeland, E.B., H.K. Blomhoff, H. Holte, E. Ruud, K. Beiske, S. Funderud, T. Godal, and R. Ohlsson. 1987. Transforming growth factor type β (TGFβ) inhibits G1 to S transition, but not activation of human B lymphocytes. Exp. Cell. Res. 171:213.

34. Belizario, J.E., and C.A. Dinarello. 1991. Interleukin 1, interleukin 6, tumor necrosis factor, and transforming growth factor β increase cell resistance to tumor necrosis factor cytotoxicity by growth arrest in the G1 phase of the cell cycle. Cancer Res. 51:2379.

35. Moses, H.L., E.Y. Yang, and J.A. Piettenpol. 1990. TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 63:245.

36. Ellingsworth, L.R., K. Brennan, K. Fok, D.M. Rosen, H. Bentz, and S.M. Seyedin. 1986. Antibodies to N-terminal portion of cartilage-inducing factor A and transforming growth factor β. J. Biol. Chem. 261:12362.

37. Keller, J.R., S.E. Jacobsen, K.T. Sill, L.R. Ellingsworth, and F.W. Ruscetti. 1991. Stimulation of granulopoiesis by transforming growth factor beta: synergy with granulocyte/macrophage-colony-stimulating factor. Proc. Natl. Acad. Sci. USA. 88:7190.

38. Jacobsen, S.E., J.R. Keller, F.W. Ruscetti, P. Kondaiah, A.B. Roberts, and L.A. Falk. 1991. Bidirectional effects of transforming growth factor β (TGF-β) on colony-stimulating factor-induced human myelopoiesis in vitro: differential effects of distinct TGF-β isoforms. Blood. 78:2239.

39. Jacobsen, S.E., F.W. Ruscetti, A.B. Roberts, and J.R. Keller. 1993. TGF-β3 is a bidirectional modulator of cytokine receptor expression on murine bone marrow cells. Differential effects of TGF-β1 and TGF-β3. J. Immunol. 151:4534.

40. Hodgson, G.S., and T.R. Bradley. 1979. Properties of hematopoietic stem cells surviving 5-fluorouracil treatment: evidence for a pre-CFU-S cell. Nature (Lond.). 28:381.

41. Van Zant, G. 1984. Studies of hematopoietic stem cells spared by 5-fluorouracil. J. Exp. Med. 159:679.

42. Harrison, D.E., and C. Lerner. 1991. Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood. 78:1237.

43. Spangrude, G.J., L. Smith, N. Uchida, K. Ikuta, S. Heimfeld, J. Friedman, and I.L. Weissman. 1991. Mouse hematopoietic stem cells. Blood. 78:1395.

44. Lerner, C., and D.E. Harrison. 1990. 5-fluorouracil spares hematopoietic stem cells responsible for long-term repopulation. Exp. Hematol. 18:114.

45. Acton, E.M., G.L. Tong, C.W. Mosher, and R.L. Wolgemuth. 1984. Intensely potent morpholinyl anthracyclines. J. Med. Chem. 27:638.

46. Carlino, J.A., and R.W. Gregory. 1993. TGF-β2 decreases chemotherapy-induced mortality in mice. J. Cell. Biochem. 17B (suppl):61 (Abstr.).

47. Odom, A.L., C.A. Hatwig, J.S. Stanley, and A.M. Benson. 1992. Biochemical determinants of Adriamycin toxicity in mouse liver, heart and intestine. Biochim. Pharmacol. 43:831.

48. Anilkumar, T.R., C.E. Sarraf, T. Hunt, and M.R. Allison. 1992. The nature of cytotoxic drug-induced cell death in murine intestinal crypts. Br. J. Cancer. 65:552.

49. Alderton, P.M., J. Gross, and M.D. Green. 1992. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 52:194.

50. Lefer, A.M., P. Tsao, N. Acki, and M.A. Palladino. 1990. Mediation of cardioprotection by transforming growth factor-β. Science (Wash. DC). 249:61.

51. Sonis, S.T., L. Lindquist, A. Van Vught, A.A. Stewart, K. Stam, G. Qu, K.K. Iwata, and J.D. Haley. 1994. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor β3. Cancer Res. 54:1135.

52. Lemoli, R.M., A. Strife, B.D. Clarkson, J.D. Haley, and S.C. Gulati. 1992. TGF-β3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro. Exp. Hematol. 20:1252.